Cover Image
市場調查報告書

全球生物製藥市場:產業分析、規模、佔有率、成長、趨勢與預測

Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

出版商 Transparency Market Research 商品編碼 309696
出版日期 內容資訊 英文 145 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球生物製藥市場:產業分析、規模、佔有率、成長、趨勢與預測 Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
出版日期: 2014年07月01日 內容資訊: 英文 145 Pages
簡介

生物製藥市場,由於慢性疾病得病率上升及全球性老年人口增加使生物藥品的需求高漲而擴大。還有各種政府相關機關也支撐生物製藥市場的成長。加上,生物醫科學的進步對生物製藥市場成長來說也隱藏非常大的可能性。另一方面,生物製藥的高成本及暢銷藥物的專利到期,妨礙生物製藥市場成長。還有生物學的注射劑相關副作用的風險,也成為生物製藥市場主要阻礙要素之一。

本報告提供全球生物製藥市場相關資料、整體市場及各市場區隔(治療性蛋白質、單株抗體、疫苗)調查、市場推動成長因素與阻礙要素、機會及近幾年的發展趨勢分析、開發平台分析、各地區的市場規模與預測等彙整資料,為您概述為以下內容。

第1章 序文

第2章 摘要整理

第3章 全球生物製藥市場:產業分析

  • 簡介
  • 市場成長的促進要素
  • 市場機會
  • 市場成長的阻礙要素

第4章 市場趨勢

  • 抗血管內皮層生長因子(VEGF)療法的利用擴大,受到生物製藥產業的歡迎
  • 基因改造生物(GMO)在生物製藥市場中重要性提高

第5章 波特的五力分析

第6章 全球市場規模與預測

第7章 市場區隔分析:治療性蛋白質

  • Enbrel
  • Lantus
  • Neulasta
  • Avonex
  • NovoLog
  • Rebif
  • Humalog
  • Aranesp
  • Epogen
  • Levemir
  • Victoza
  • Betaseron
  • Neupogen
  • Eylea

第8章市場區隔分析: 各mAb(單株抗體)

  • Humira(hyumira)
  • Remicade(REMICADE)
  • Rituxan(Rituxan)
  • Avastin(Avastin)
  • Herceptin(Herceptin)
  • Lucentis(Lucentis)

第9章 市場區隔分析:各疫苗

  • Prenvar 13
  • Gardasil
  • Fluzone
  • Varivax
  • Cervarix

第10章 地區分析

  • 北美情形
  • 歐洲
  • 亞洲
  • 其他

第11章 生物製藥的開發平台

  • 正在開發的生物製藥:自體免疫疾病
  • 正在開發的生物製藥:血液疾病
  • 正在開發的生物製藥:癌症、相關疾病
  • 正在開發的生物製藥:糖尿病、心血管疾病

第12章 競爭情形

第13章 企業簡介

  • Pfizer Inc.
    • 企業概要
    • 產品、市場區隔
    • 財務實際成果
    • 策略性發展
  • Abbott Laboratories
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Biogen Idec

圖表清單

目錄

Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody (mAb) and vaccines. The biological drugs market is growing due to the increasing prevalence of chronic diseases and the demand for biological drugs is growing due to the increase in the global geriatric population. Moreover, various government associations are also supporting in growth of biological drugs market. Furthermore, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market.

On the other hand, high cost of biologic drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of the biological drugs market.

The report provides in-depth analysis and estimation of the biological drugs market from 2014 to 2020, considering 2013 as the base year for calculation. Additionally, data pertaining to current market dynamics including market drivers, restraints, trends and recent developments has been provided in the biological drugs market report. The global biological drugs market is categorized based on therapeutic protein, monoclonal antibody (mAb), vaccine and geography. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix.

Under geographic analysis, the report identifies and analyses the biological drugs market size and provides forecasts for the markets in North America, Europe, Asia and Rest of the World (RoW). Major players operating in the biological drugs market are Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc. and Biogen Idec. These key market players have been profiled based on attributes such as company overview, recent developments, growth strategies, sustainability and financial overview.

Table of Contents

Chapter 1 - Preface

  • 1.1. Report Description
  • 1.2. Research methodology
    • 1.2.1. Sources
      • 1.2.1.1. Secondary Research
      • 1.2.1.2. Primary Research
      • 1.2.1.3. Assumptions

Chapter 2 - Executive Summary

Chapter 3 - Global Biological Drugs Market - Industry Analysis

  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Increasing prevalence of chronic diseases enhance the market growth
    • 3.2.2. Globally geriatric population increases the demand of biological drugs
    • 3.2.3. Various government associations are promoting usage of biological drugs
  • 3.3. Market Opportunities
    • 3.3.1. Advancement in biomedical science promises to boost the development of new biological products
  • 3.4. Restraints
    • 3.4.1. High cost of biological drugs impedes market growth
    • 3.4.2. Patent expiration of various blockbuster biological drugs
    • 3.4.3. Risk of adverse effects associated with biological injectable medicines

Chapter 4 - Market Trends

  • 4.1.1. Increasing use of anti-Vascular Endothelial Growth Factor (VEGF) therapy is gaining popularity in biopharmaceutical industry
  • 4.1.2. Genetically Modified Organisms (GMOs) are gaining importance in biological drugs market

Chapter 5 - Porter's Five Forces Analysis

  • 5.1.1. Bargaining power of suppliers
  • 5.1.2. Bargaining power of buyers
  • 5.1.3. Threat of new entrants
  • 5.1.4. Threat of substitutes
  • 5.1.5. Degree of competition

Chapter 6 - Global Market Size and Forecast

Chapter 7 - Segment Analysis, by Therapeutic Protein

  • 7.1. Enbrel
  • 7.2. Lantus
  • 7.3. Neulasta
  • 7.4. Avonex
  • 7.5. NovoLog
  • 7.6. Rebif
  • 7.7. Humalog
  • 7.8. Aranesp
  • 7.9. Epogen
  • 7.10. Levemir
  • 7.11. Victoza
  • 7.12. Betaseron
  • 7.13. Neupogen
  • 7.14. Eylea

Chapter 8 - Segment Analysis, by mAb

  • 8.1. Humira
  • 8.2. Remicade
  • 8.3. Rituxan
  • 8.4. Avastin
  • 8.5. Herceptin
  • 8.6. Lucentis

Chapter 9 - Segment Analysis, by Vaccine

  • 9.1. Prenvar 13
  • 9.2. Gardasil
  • 9.3. Fluzone
  • 9.4. Varivax
  • 9.5. Cervarix

Chapter 10 - Regional Analysis

  • 10.1. Scenario in North America
  • 10.2. Scenario in Europe
  • 10.3. Scenario in Asia
  • 10.4. Rest of the World (RoW)

Chapter 11 - Pipeline Biologic Drugs

  • 11.1. Biological drugs under development for auto-immune diseases
  • 11.2. Biological drugs under development for blood diseases
  • 11.3. Biological drugs under development for cancer and related conditions
  • 11.4. Biological drugs under development for diabetes and cardiovascular diseases

Chapter 12 - Competitive Landscape

Chapter 13 - Company Profiles

  • 13.1. Pfizer Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Product & Segments
    • 13.1.3. Financial Performance
    • 13.1.4. Strategic Developments
  • 13.2. Abbott Laboratories
    • 13.2.1. Company Overview
    • 13.2.2. Product & Segments
    • 13.2.3. Financial Performance
    • 13.2.4. Strategic Developments
  • 13.3. Novartis AG
    • 13.3.1. Company Overview
    • 13.3.2. Product & Segments
    • 13.3.3. Financial Performance
    • 13.3.4. Strategic Developments
  • 13.4. Eli Lilly and Company
    • 13.4.1. Company Overview
    • 13.4.2. Product & Segments
    • 13.4.3. Financial Performance
    • 13.4.4. Strategic Developments
  • 13.5. GlaxoSmithKline plc.
    • 13.5.1. Company Overview
    • 13.5.2. Product & Segments
    • 13.5.3. Financial Performance
    • 13.5.4. Strategic Developments
  • 13.6. Bristol-Myers Squibb Company
    • 13.6.1. Company Overview
    • 13.6.2. Product & Segments
    • 13.6.3. Financial Performance
    • 13.6.4. Strategic Developments
  • 13.7. Merck & Co., Inc.
    • 13.7.1. Company Overview
    • 13.7.2. Product & Segments
    • 13.7.3. Financial Performance
    • 13.7.4. Strategic Developments
  • 13.8. Amgen Inc.
    • 13.8.1. Company Overview
    • 13.8.2. Product & Segments
    • 13.8.3. Financial Performance
    • 13.8.4. Strategic Developments
  • 13.9. Baxter International Inc.
    • 13.9.1. Company Overview
    • 13.9.2. Product & Segments
    • 13.9.3. Financial Performance
    • 13.9.4. Strategic Developments
  • 13.10. Biogen Idec
    • 13.10.1. Company Overview
    • 13.10.2. Product & Segments
    • 13.10.3. Financial Performance
    • 13.10.4. Strategic Developments

List of Figures

  • FIG. 1: Biological Drugs Market, by therapeutic proteins, mAbs and vaccine
  • FIG. 2: Geriatric population in major countries, % in older ages (2000-2050)
  • FIG. 3: Biological Drugs Market: Porter's five force analysis
  • FIG. 4: Global market for biological drugs, by geography 2013 (% share)
  • FIG. 5: Global market for biological drugs, by segment 2013 (% share)
  • FIG. 6: Global market for Enbrel, by geography 2013 (% share)
  • FIG. 7: Global market for Lantus, by geography 2013 (% share)
  • FIG. 8: Global market for Neulasta, by geography 2013 (% share)
  • FIG. 9: Global market for Avonex, by geography 2013 (% share)
  • FIG. 10: Global market for NovoLog, by geography 2013 (% share)
  • FIG. 11: Global market for Rebif, by geography 2013 (% share)
  • FIG. 12: Global market for Humalog, by geography 2013 (% share)
  • FIG. 13: Global market for Aranesp, by geography 2013 (% share)
  • FIG. 14: Global market for Epogen, by geography 2013 (% share)
  • FIG. 15: Global market for Levemir, by geography 2013 (% share)
  • FIG. 16: Global market for Victoza, by geography 2013 (% share)
  • FIG. 17: Global market for Betaseron, by geography 2013 (% share)
  • FIG. 18: Global market for Neupogen, by geography 2013 (% share)
  • FIG. 19: Global market for Eylea, by geography 2013 (% share)
  • FIG. 20: Global market for Humira by geography 2013 (% share)
  • FIG. 21: Global market for Remicade, by geography 2013 (% share)
  • FIG. 22: Global market for Rituxan, by geography 2013 (% share)
  • FIG. 23: Global market for Avastin, by geography 2013 (% share)
  • FIG. 24: Global market for Herceptin, by geography 2013 (% share)
  • FIG. 25: Global market for Lucentis, by geography 2013 (% share)
  • FIG. 26: Global market for Prevnar 13, by geography 2013 (% share)
  • FIG. 27: Global market for Gardasil, by geography 2013 (% share)
  • FIG. 28: Global market for Fluzone, by geography 2013 (% share)
  • FIG. 29: Global market for Varivax, by geography 2013 (% share)
  • FIG. 30: Global market for Cervarix, by geography 2013 (% share)
  • FIG. 31: The North American market for biological drugs, by country 2013 (% share)
  • FIG. 32: The North American market for biological drugs, by therapeutic protein 2013 (% share)
  • FIG. 33: The North American market for biological drugs, by mAb 2013 (% share)
  • FIG. 34: The North American market for biological drugs, by vaccine 2013 (% share)
  • FIG. 35: The European market for biological drugs, by country 2013 (% share)
  • FIG. 36: The European market for biological drugs, by therapeutic protein 2013 (% share)
  • FIG. 37: The European market for biological drugs, by mAb 2013 (% share)
  • FIG. 38: The European market for biological drugs, by vaccine 2013 (% share)
  • FIG. 39: The Asian market for biological drugs, by country 2013 (% share)
  • FIG. 40: The Asian market for biological drugs, by therapeutic protein 2013 (% share)
  • FIG. 41: The Asian market for biological drugs, by mAb 2013 (% share)
  • FIG. 42: The Asian market for biological drugs, by vaccine 2013 (% share)
  • FIG. 43: Competitive landscape of biological drugs market
  • FIG. 44: Pfizer revenue and net income 2011-2013 (USD million)
  • FIG. 45: Abbott net sales and net earnings 2011-2013 (USD million)
  • FIG. 46: Novartis net sales and net income 2011-2013 (USD million)
  • FIG. 47: Lilly revenue and net income 2011-2013 (USD million)
  • FIG. 48: GlaxoSmithKline turnover and profit 2011-2013 (USD million)
  • FIG. 49: Bristol-Myers Squibb revenue and net earnings 2011-2013 (USD million)
  • FIG. 50: Merck sales and net income 2011-2013 (USD million)
  • FIG. 51: Amgen revenue and net income 2011-2013 (USD million)
  • FIG. 52: Baxter net sales and net income 2011-2013 (USD million)
  • FIG. 53: Biogen Idec revenue and net income 2011-2013 (USD million)

List of Tables

  • TABLE 1: Market Snapshot: Global market for biological drugs (2014 & 2020)
  • TABLE 2: Drivers for global biological drugs market: Impact analysis
  • TABLE 3: Major biological drugs and their treatment for diseases
  • TABLE 4: Restraints for global biological drugs market: Impact analysis
  • TABLE 5: Major biological drugs and their adverse effects 21
  • TABLE 6: Global market for biological drugs, by geography 2009-2013 (USD million)
  • TABLE 7: Global market for biological drugs, by geography 2014-2020 (USD million)
  • TABLE 8: Global market for biological drugs , by segment 2009-2013 (USD million)
  • TABLE 9: Global market for biological drugs, by segment 2014-2020 (USD million)
  • TABLE 10: Global market for Enbrel , by geography 2009-2013 (USD million)
  • TABLE 11: Global market for Enbrel, by geography 2014-2020 (USD million)
  • TABLE 12: Global market for Lantus , by geography 2009-2013 (USD million)
  • TABLE 13: Global market for Lantus, by geography 2014-2020 (USD million)
  • TABLE 14: Global market for Neulasta , by geography 2009-2013 (USD million)
  • TABLE 15: Global market for Neulasta, by geography 2014-2020 (USD million)
  • TABLE 16: Global market for Avonex, by geography 2009-2013 (USD million)
  • TABLE 17: Global market for Avonex, by geography 2014-2020 (USD million)
  • TABLE 18: Global market for NovoLog , by geography 2009-2013 (USD million)
  • TABLE 19: Global market for NovoLog, by geography 2014-2020 (USD million)
  • TABLE 20: Global market for Rebif, by geography 2009-2013 (USD million)
  • TABLE 21: Global market for Rebif, by geography 2014-2020 (USD million)
  • TABLE 22: Global market for Humalog, by geography 2009-2013 (USD million)
  • TABLE 23: Global market for Humalog, by geography 2014-2020 (USD million)
  • TABLE 24: Global market for Aranesp, by geography 2009-2013 (USD million)
  • TABLE 25: Global market for Aranesp, by geography 2014-2020 (USD million)
  • TABLE 26: Global market for Epogen, by geography 2009-2013 (USD million)
  • TABLE 27: Global market for Epogen, by geography 2014-2020 (USD million)
  • TABLE 28: Global market for Levemir, by geography 2009-2013 (USD million)
  • TABLE 29: Global market for Levemir, by geography 2014-2020 (USD million)
  • TABLE 30: Global market for Victoza, by geography 2009-2013 (USD million)
  • TABLE 31: Global market for Victoza, by geography 2014-2020 (USD million)
  • TABLE 32: Global market for Betaseron, by geography 2009-2013 (USD million)
  • TABLE 33: Global market for Betaseron, by geography 2014-2020 (USD million)
  • TABLE 34: Global market for Neupogen, by geography 2009-2013 (USD million)
  • TABLE 35: Global market for Neupogen, by geography 2014-2020 (USD million)
  • TABLE 36: Global market for Eylea, by geography 2009-2013 (USD million)
  • TABLE 37: Global market for Eylea, by geography 2014-2020 (USD million)
  • TABLE 38: Global market for Humira, by geography 2009-2013 (USD million)
  • TABLE 39: Global market for Humira, by geography 2014-2020 (USD million)
  • TABLE 40: Global market for Remicade, by geography 2009-2013 (USD million)
  • TABLE 41: Global market for Remicade, by geography 2014-2020 (USD million)
  • TABLE 42: Global market for Rituxan, by geography 2009-2013 (USD million)
  • TABLE 43: Global market for Rituxan, by geography 2014-2020 (USD million)
  • TABLE 44: Global market for Avastin, by geography 2009-2013 (USD million)
  • TABLE 45: Global market for Avastin, by geography 2014-2020 (USD million)
  • TABLE 46: Global market for Herceptin, by geography 2009-2013 (USD million)
  • TABLE 47: Global market for Herceptin, by geography 2014-2020 (USD million)
  • TABLE 48: Global market for Lucentis, by geography 2009-2013 (USD million)
  • TABLE 49: Global market for Lucentis, by geography 2014-2020 (USD million)
  • TABLE 50: Global market for Prevnar 13, by geography 2009-2013 (USD million)
  • TABLE 51: Global market for Prevnar 13, by geography 2014-2020 (USD million)
  • TABLE 52: Global market for Gardasil, by geography 2009-2013 (USD million)
  • TABLE 53: Global market for Gardasil, by geography 2014-2020 (USD million)
  • TABLE 54: Global market for Fluzone, by geography 2009-2013 (USD million)
  • TABLE 55: Global market for Fluzone, by geography 2014-2020 (USD million)
  • TABLE 56: Global market for Varivax, by geography 2009-2013 (USD million)
  • TABLE 57: Global market for Varivax, by geography 2014-2020 (USD million)
  • TABLE 58: Global market for Cervarix, by geography 2009-2013 (USD million)
  • TABLE 59: Global market for Cervarix, by geography 2014-2020 (USD million)
  • TABLE 60: The North American market for biological drugs, by country 2009-2013 (USD million)
  • TABLE 61: The North American market for biological drugs, by country 2014-2020 (USD million)
  • TABLE 62: The North American market for biological drugs, by therapeutic protein 2009-2013 (USD million)
  • TABLE 63: The North American market for biological drugs, by therapeutic protein 2014-2020 (USD million)
  • TABLE 64: The North American market for biological drugs, by mAb 2009-2013 (USD million)
  • TABLE 65: The North American market for biological drugs, by mAb 2014-2020 (USD million)
  • TABLE 66: The North American market for biological drugs, by vaccine 2009-2013 (USD million)
  • TABLE 67: The North American market for biological drugs, by vaccine 2014-2020 (USD million)
  • TABLE 68: The European market for biological drugs, by country 2009-2013 (USD million)
  • TABLE 69: The European market for biological drugs, by country 2014-2020 (USD million)
  • TABLE 70: The European market for biological drugs, by therapeutic protein 2009-2013 (USD million)
  • TABLE 71: The European market for biological drugs, by therapeutic protein 2014-2020 (USD million)
  • TABLE 72: The European market for biological drugs, by mAb 2009-2013 (USD million)
  • TABLE 73: The European market for biological drugs, by mAb 2014-2020 (USD million)
  • TABLE 74: The European market for biological drugs, by vaccine 2009-2013 (USD million)
  • TABLE 75: The European market for biological drugs, by vaccine 2014-2020 (USD million)
  • TABLE 76: The Asian market for biological drugs, by country 2009-2013 (USD million)
  • TABLE 77: The Asian market for biological drugs, by country 2014-2020 (USD million)
  • TABLE 78: The Asian market for biological drugs, by therapeutic protein 2009-2013 (USD million)
  • TABLE 79: The Asian market for biological drugs, by therapeutic protein 2014-2020 (USD million)
  • TABLE 80: The Asian market for biological drugs, by mAb 2009-2013 (USD million) 101
  • TABLE 81: The Asian market for biological drugs, by mAb 2014-2020 (USD million) 102
  • TABLE 82: The Asian market for biological drugs, by vaccine 2009-2013 (USD million)
  • TABLE 83: The Asian market for biological drugs, by vaccine 2014-2020 (USD million)
  • TABLE 84: Some pipeline biological drugs for auto-immune diseases
  • TABLE 85: Some pipeline biological drugs for blood diseases
  • TABLE 86: Some pipeline biological drugs for cancer and related conditions
  • TABLE 87: Some pipeline biological drugs for diabetes and cardiovascular diseases
  • TABLE 88: Pfizer major product segments
  • TABLE 89: Abbott major product categories
  • TABLE 90: Novartis product segments
  • TABLE 91: Lilly product segments
  • TABLE 92: GlaxoSmithKline product segments
  • TABLE 93: Bristol-Myers Squibb key product and brands
  • TABLE 94: Merck key product categories
  • TABLE 95: Amgen product category
  • TABLE 96: Baxter major product categories
  • TABLE 97: Biogen Idec major therapies and their uses
Back to Top